News Amgen Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			Pre-market 07:00:39 am
265.5 ^USD	-0.66%		270.3	+1.79%

03:19pm	TD Cowen Cuts Price Target on Amgen to $360 From $370, Buy Rating Kept	MT
01:47pm	Goldman Sachs Adjusts Amgen Price Target to $359 From $361, Maintains Buy Rating	MT

TD Cowen Cuts Price Target on Amgen to $360 From $370, Buy Rating Kept	09:19am	MT
Goldman Sachs Adjusts Amgen Price Target to $359 From $361, Maintains Buy Rating	07:47am	MT
Neumora's early-stage schizophrenia drug study put on hold	06:52am	RE
BMO Lowers Price Target on Amgen to $336 From $343	Apr. 12	MT
Amgen : CEO Bob Bradway's 2023 Letter to Shareholders	Apr. 10	PU
Amgen : Chairman and CEO Letter and Amgen Inc. 2023 Annual Report	Apr. 10	PU
Morgan Stanley Raises 2024, 2025 EPS Estimates for Regeneron Pharmaceuticals, Amgen	Apr. 09	MT
Morgan Stanley Cuts Price Target on Amgen to $271 From $278, Keeps Equalweight Rating	Apr. 09	MT
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 05	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 04	RE
Amgen : How the LATTICE™ Consortium Is Igniting Action and Innovation in Cardiovascular Care	Apr. 04	PU
US takes next step in Medicare drug price negotiations with pharma companies	Apr. 02	RE
Updates On Aflibercept BPCIA Litigation	Mar. 26	AQ
Amgen : Jean-Charles Soria Elected to American Association for Cancer Research Board of Directors	Mar. 19	PU
FDA Approves Sandoz Denosumab Biosimilars	Mar. 18	AQ
USPTO Releases Post-Amgen Guidance For Determining Enablement	Mar. 15	AQ
USPTO Updates Guidance On Enablement	Mar. 11	AQ
Amgen Presents New Research on Otezla at AAD 2024	Mar. 09	CI
Amgen Keeps Q2 Dividend at $2.25 a Share, Payable June 7 to Stockholders of Record May 17	Mar. 06	MT
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND	Mar. 06	PR

No results for this search